This picture is used only for representative purposes. | Photo Credit: Getty Images/Istockphoto
A significant number of cancer drugs are, beyond the extent of the current price control mechanisms, 163. The report of the petition committee, which was observed at the beginning of this week in its report on recommendations in parliament.
With the announcement of the National List of basic medicinal products 2022, the number of anti -cancer drugs under the price control increased from 40 in 2011 to 63 in 2022. However, a significant number of oncological drugs are not included in the drug order (DPCO), 2013 and therefore no legal price is stated.
“This regulatory Neinclusion has led to an excessive and often inaccessible price, limiting access to a large part of the population of patients,” he said.
The government should take urgent measures to extend the scope of DPCO to include the widest possible range of cancer drugs, the petitions recommended in its report. In addition, regular and comprehensive market evaluation should be introduced to monitor the predominant prices of drugs and trends in availability, she said.
The quality of generics available in the country should be monitored and maintained because many healthcare workers are hesitant to prescribe generations because they are not certified according to good manufacturing procedures by the World Health Organization, the report said.
While there are provisions for accelerated access to new cancer drugs, the report states that regulatory delays, insufficient domestic research and development and price restrictions reduce early and fair approach.
“Home research infrastructure should be strengthened, a value based on the values that is preferred should be effectively regulatory paths and measures to support indigenous development of new cancer therapies should be taken.
It seemed that between the medical institutions of the private sector and the Ministry of Health and the good life conditions of the Department of Trade Unions regarding the approval of clinical trials in the country, the report said. Therefore, the Committee recommended in its report should be cooperation between them in order to obtain maximum results for the greater benefit of patients.
Platforms, including the consortium for cancer research in India, should be entrusted with the publication of annual performance and progress reports, including documentation on the extent that the research outputs were reflected in clinical practice. “The mechanisms for systematic monitoring of the patient’s results and the cost -effectiveness evaluation by accepting the treatment instructions must also be introduced to support evidence -based policy,” the report said.
Read more
Published – August 21, 2025 21:33
